HRP20161743T1 - Spojevi benzofurana namijenjeni liječenju infekcija virusom hepatitisa c - Google Patents

Spojevi benzofurana namijenjeni liječenju infekcija virusom hepatitisa c Download PDF

Info

Publication number
HRP20161743T1
HRP20161743T1 HRP20161743TT HRP20161743T HRP20161743T1 HR P20161743 T1 HRP20161743 T1 HR P20161743T1 HR P20161743T T HRP20161743T T HR P20161743TT HR P20161743 T HRP20161743 T HR P20161743T HR P20161743 T1 HRP20161743 T1 HR P20161743T1
Authority
HR
Croatia
Prior art keywords
hepatitis
treatment
virus infections
methyl
benzofuran
Prior art date
Application number
HRP20161743TT
Other languages
English (en)
Croatian (hr)
Inventor
Pek Yoke Chong
John F. Miller
Andrew James Peat
John Brad Shotwell
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47746761&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20161743(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of HRP20161743T1 publication Critical patent/HRP20161743T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
HRP20161743TT 2011-08-19 2012-08-10 Spojevi benzofurana namijenjeni liječenju infekcija virusom hepatitisa c HRP20161743T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161525440P 2011-08-19 2011-08-19
US201261650681P 2012-05-23 2012-05-23
PCT/US2012/050268 WO2013028371A1 (en) 2011-08-19 2012-08-10 Benzofuran compounds for the treatment of hepatitis c virus infections
EP12826498.3A EP2744332B1 (en) 2011-08-19 2012-08-10 Benzofuran compounds for the treatment of hepatitis c virus infections

Publications (1)

Publication Number Publication Date
HRP20161743T1 true HRP20161743T1 (hr) 2017-02-24

Family

ID=47746761

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20161743TT HRP20161743T1 (hr) 2011-08-19 2012-08-10 Spojevi benzofurana namijenjeni liječenju infekcija virusom hepatitisa c

Country Status (38)

Country Link
US (2) US8927593B2 (enExample)
EP (2) EP2744332B1 (enExample)
JP (2) JP6367712B2 (enExample)
KR (1) KR101913800B1 (enExample)
CN (1) CN103732065B (enExample)
AR (1) AR087563A1 (enExample)
AU (1) AU2012299295B2 (enExample)
BR (1) BR112014002845A2 (enExample)
CA (1) CA2844086A1 (enExample)
CL (2) CL2014000393A1 (enExample)
CO (1) CO6862153A2 (enExample)
CR (1) CR20140078A (enExample)
CY (1) CY1118399T1 (enExample)
DK (1) DK2744332T3 (enExample)
DO (1) DOP2014000034A (enExample)
EA (1) EA032841B1 (enExample)
ES (1) ES2611731T3 (enExample)
HR (1) HRP20161743T1 (enExample)
HU (1) HUE030300T2 (enExample)
IL (1) IL230487B (enExample)
IN (1) IN2014CN00572A (enExample)
JO (1) JO3281B1 (enExample)
LT (1) LT2744332T (enExample)
MA (1) MA35443B1 (enExample)
ME (1) ME02588B (enExample)
MX (1) MX354676B (enExample)
PE (1) PE20141201A1 (enExample)
PH (1) PH12014500385A1 (enExample)
PL (1) PL2744332T3 (enExample)
PT (1) PT2744332T (enExample)
RS (1) RS55462B1 (enExample)
SG (1) SG10201606883QA (enExample)
SI (1) SI2744332T1 (enExample)
SM (2) SMT201700028T1 (enExample)
TW (1) TWI538915B (enExample)
UY (1) UY34274A (enExample)
WO (1) WO2013028371A1 (enExample)
ZA (1) ZA201401020B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12014500381A1 (en) 2011-08-17 2021-07-12 Glaxosmithkline Llc Therapeutic methods
US8927593B2 (en) 2011-08-19 2015-01-06 Glaxo Group Limited Benzofuran compounds for the treatment of hepatitis C virus infections
MA40844A (fr) 2014-11-10 2017-09-20 Glaxosmithkline Ip No 2 Ltd Compositions pharmaceutiques à action prolongée pour l'hépatite c
US10308937B2 (en) * 2014-11-10 2019-06-04 Glaxosmithkline Intellectual Property (No. 2) Limited Combination long acting compositions and methods for Hepatitis C
KR20180006522A (ko) 2016-07-07 2018-01-18 삼성디스플레이 주식회사 액정 조성물 및 이를 포함하는 액정 표시 장치
US11738088B2 (en) 2016-08-01 2023-08-29 University of Pittsburgh—of the Commonwealth System of Higher Education Boryl ethers, carbonates, and cyclic acetals as oxidatively-triggered drug delivery vehicles
BR112019018230A2 (pt) * 2017-03-02 2020-07-21 Assembly Biosciences, Inc. compostos de sulfamida cíclica e métodos de sua utilização
JP7133023B2 (ja) * 2018-01-17 2022-09-07 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Pi4kiiiベータ阻害剤
US20230038124A1 (en) * 2019-10-25 2023-02-09 Sumitomo Pharma Co., Ltd. Novel substituted condensed ring compound
CN111026203B (zh) * 2019-12-02 2021-01-26 宁波德晶元科技有限公司 一种适用于真空热水壶的加热控制方法与系统
WO2022133420A1 (en) * 2020-12-18 2022-06-23 Boehringer Ingelheim Animal Health USA Inc. Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
WO2001002424A2 (en) * 1999-07-07 2001-01-11 Du Pont Pharmaceuticals Company Peptide boronic acid inhibitors of hepatitis c virus protease
CA2435146C (en) 2001-01-25 2011-03-29 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Formulation of boronic acid compounds
US7265152B2 (en) * 2002-11-01 2007-09-04 Viropharma Incorporated Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases
BRPI0619132A2 (pt) 2005-12-01 2011-09-13 Wyeth Corp composto métodos para inibir a replicação de um vìrus de hepatite c, para tratar ou prevenir uma infecção viral de hepatite c em um mamìfero e para inibir rna polimerase dependente do rna de hepatite c, e, composição farmacêutica
RU2642628C2 (ru) 2006-02-16 2018-01-25 Анакор Фармасьютикалз, Инк. Бор-содержащие малые молекулы в качестве противовоспалительных средств
BRPI0711155A2 (pt) * 2006-05-02 2011-08-23 Anacor Pharmaceuticals Inc terapêuticos contendo boro resistentes hidroliticamente e métodos de uso
US20070286822A1 (en) 2006-06-12 2007-12-13 Anacor Pharmaceuticals Inc. Compounds for the Treatment of Periodontal Disease
ES2569660T3 (es) * 2007-06-08 2016-05-12 Mannkind Corporation Inhibidores de la IRE-1alfa
GB0719366D0 (en) * 2007-10-03 2007-11-14 Smithkline Beecham Corp Compounds
WO2009111676A2 (en) 2008-03-06 2009-09-11 Anacor Pharmaceuticals, Inc Boron-containing small molecules as anti-inflammatory agents
ATE539070T1 (de) * 2008-02-14 2012-01-15 Hoffmann La Roche Heterozyklische antivirale verbindungen
WO2009137493A1 (en) 2008-05-05 2009-11-12 Wyeth 2-substituted benzofuran compounds to treat infection with hepatitis c virus
WO2009137500A1 (en) * 2008-05-05 2009-11-12 Wyeth 6-substituted benzofuran compounds to treat infection with hepatitis c virus
TW201008933A (en) 2008-08-29 2010-03-01 Hutchison Medipharma Entpr Ltd Pyrimidine compounds
WO2010027975A1 (en) 2008-09-04 2010-03-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2011050284A1 (en) * 2009-10-23 2011-04-28 Glaxosmithkline Llc Pyrazolylpyridine antiviral agents
AR080185A1 (es) * 2010-02-19 2012-03-21 Glaxo Group Ltd Derivados de acido boronico y benzofurano, composiciones farmaceuticas que los contienen,y uso de los mismos en el tratamiento y/o prevencion de infecciones virales, en particular por el virus de hepatitis c(hcv).
WO2011106929A1 (en) 2010-03-02 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus ns5b polymerase
TW201136919A (en) 2010-03-02 2011-11-01 Merck Sharp & Amp Dohme Corp Inhibitors of hepatitis C virus NS5B polymerase
AU2011329485A1 (en) * 2010-11-18 2013-04-18 Glaxo Group Limited Compounds
AU2011329486A1 (en) 2010-11-18 2013-04-18 Glaxo Group Limited Compounds
WO2013025975A1 (en) * 2011-08-17 2013-02-21 Glaxosmithkline Llc Combination treatments for hepatitis c
PH12014500381A1 (en) * 2011-08-17 2021-07-12 Glaxosmithkline Llc Therapeutic methods
US8927593B2 (en) 2011-08-19 2015-01-06 Glaxo Group Limited Benzofuran compounds for the treatment of hepatitis C virus infections

Also Published As

Publication number Publication date
CN103732065B (zh) 2016-10-26
UY34274A (es) 2013-04-05
TW201321390A (zh) 2013-06-01
CN103732065A (zh) 2014-04-16
BR112014002845A2 (pt) 2017-02-21
IN2014CN00572A (enExample) 2015-04-03
US8927593B2 (en) 2015-01-06
MX2014001989A (es) 2014-02-27
LT2744332T (lt) 2017-01-10
CO6862153A2 (es) 2014-02-10
TWI538915B (zh) 2016-06-21
AU2012299295B2 (en) 2016-03-31
ES2611731T3 (es) 2017-05-10
MX354676B (es) 2018-03-15
PE20141201A1 (es) 2014-10-03
US20130237501A1 (en) 2013-09-12
JP2014527529A (ja) 2014-10-16
SG10201606883QA (en) 2016-10-28
SMT201700028T1 (it) 2017-03-08
WO2013028371A1 (en) 2013-02-28
HUE030300T2 (en) 2017-04-28
IL230487A0 (en) 2014-03-31
EA032841B1 (ru) 2019-07-31
MA35443B1 (fr) 2014-09-01
CA2844086A1 (en) 2013-02-28
EP3199531A1 (en) 2017-08-02
US9682999B2 (en) 2017-06-20
JP6367712B2 (ja) 2018-08-01
RS55462B1 (sr) 2017-04-28
EP2744332B1 (en) 2016-10-26
ME02588B (me) 2017-06-20
CY1118399T1 (el) 2017-06-28
AR087563A1 (es) 2014-04-03
US20150080343A1 (en) 2015-03-19
AU2012299295A1 (en) 2014-02-20
SI2744332T1 (sl) 2017-01-31
IL230487B (en) 2019-06-30
EP2744332A1 (en) 2014-06-25
CL2014000393A1 (es) 2014-08-01
CL2017000293A1 (es) 2017-10-06
EP2744332A4 (en) 2015-01-14
PL2744332T3 (pl) 2017-03-31
PT2744332T (pt) 2017-01-24
DOP2014000034A (es) 2014-06-01
JP2017125010A (ja) 2017-07-20
KR101913800B1 (ko) 2018-11-01
ZA201401020B (en) 2020-11-25
EA201490213A1 (ru) 2014-07-30
CR20140078A (es) 2014-03-20
SMT201700028B (it) 2017-03-08
KR20140054287A (ko) 2014-05-08
PH12014500385A1 (en) 2020-06-22
JO3281B1 (ar) 2018-09-16
DK2744332T3 (en) 2017-01-16

Similar Documents

Publication Publication Date Title
ME02588B (me) Jedinjenja benzofurana za lečenje virusnih infekcija hepatitisa c
SMT201600142B (it) Indoli come agenti antivirali contro il virus respiratorio sinciziale
EA201390885A1 (ru) Азаиндолы в качестве противовирусных агентов против респираторного синцитиального вируса
PY1153144A (es) Inhibidores macrocíclicos de virus flaviviridae
JP2015522045A5 (enExample)
EA201790661A2 (ru) Ингибиторы вируса гепатита c
CO6561783A2 (es) Inhibidores del virus flaviviridae
EA201591244A1 (ru) Противовирусные соединения
ECSP12011684A (es) Inhibidores de los virus flaviviridae.
LT2694484T (lt) Pirimidino dariniai, skirti virusinių infekcijų gydymui
CL2013003360A1 (es) “compuestos derivados de 4-aril-n-[3-(sulfonimidoil)fenil]-1,3,5-triazin-2-amina sustituidos, inhibidores cdk; compuestos intermediarios, composición y combinación farmacéutica que los comprende; y su uso en el tratamiento de enfermedades hiperproliferativas, infecciosas inducidas por virus y/o cardiovasculares”. pct
EA201492205A1 (ru) Макроциклические ингибиторы вирусов flaviviridae
EA201201377A1 (ru) Определенные аминопиридазины, композиции на их основе и способы их использования
EA201490596A1 (ru) Новые производные дигидрохинолин-2-она
EA201501142A1 (ru) Гетероциклические соединения в качестве средств для борьбы с вредителями
EA201591397A1 (ru) Хиноксалиноны и дигидрохиноксалиноны как антивирусные средства против респираторно-синцитиального вируса
UA113062C2 (xx) Похідні 5-фтор-4-іміно-3-(заміщеного)-3,4-дигідропіримідин-2(1h)ону
EP2635124A4 (en) ALKYLSULFINYL-SUBSTITUTED THIAZOLIDE COMPOUNDS
EA201491525A1 (ru) Спиро[2.4]гептаны для лечения инфекций, вызванных flaviviridae
EA201591512A1 (ru) Борсодержащие молекулы, способы и составы
EA201590022A1 (ru) Новые производные 1,3-дигидро-2h-бензимидазол-2-она, замещенные гетероциклами, в качестве противовирусных средств против респираторного синцитиального вируса
EA201400058A1 (ru) Соединения и композиции на основе амидопиридиловых эфиров и их применение против паразитов
EA201891804A1 (ru) Тетрациклиновые соединения
CL2014000815A1 (es) Compuestos derivados de 2-metoxibenzamidas insecticidas; composiciones insecticidas.
KR101501876B9 (ko) 자일리톨을 유효성분으로 함유하는 인플루엔자 바이러스 감염증 예방 또는 치료용 조성물